Selecta Biosciences, Inc. Debt/Assets

Debt/Assets of SELB for past 10 years: annual, quarterly and twelve month trailing (TTM) including Debt/Assets growth rates and interactive chart.

Highlights and Quick Summary

  • Debt/Assets for the quarter ending December 30, 2020 was 21.37% (a 9.42% increase compared to previous quarter)
  • Year-over-year quarterly Debt/Assets decreased by -32.63%
  • Annual Debt/Assets for 2020 was 21.37% (a 10.38% increase from previous year)
  • Annual Debt/Assets for 2019 was 19.36% (a -59.73% decrease from previous year)
  • Annual Debt/Assets for 2018 was 48.08% (a 131.04% increase from previous year)
Visit for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Debt/Assets of Selecta Biosciences, Inc.

Most recent Debt/Assetsof SELB including historical data for past 10 years.

Interactive Chart of Debt/Assets of Selecta Biosciences, Inc.

Selecta Biosciences, Inc. Debt/Assets for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 21.37% 19.53% 35.37% 31.72% 21.37%
2019 19.36% 52.92% 45.9% 34.36% 19.36%
2018 48.08% 35.31% 28.88% 23.49% 48.08%
2017 20.81% 19.1% 8.84% 15.42% 20.81%
2016 13.49% 13.96% 13.04% 0.0% 13.49%
2015 0.0% 0.0% 0.0% 27.68%
2014 33.26% 33.3%

Business Profile of Selecta Biosciences, Inc.

Sector: Healthcare
Industry: Biotechnology
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's proprietary pipeline includes enzymes therapies, gene therapies, and other products and product candidates affected by undesired immune responses. Its lead product is SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout, as well as develops a product candidate to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and IgA vasculitis. The company also engages in the development of gene therapy product candidates that are in preclinical development, including MMA-101, a product candidate for the treatment methylmalonic academia; SEL-313, a product candidate to treat ornithine transcarbamylase deficiency; SEL-399, a product candidate to indicate appropriate dose of ImmTOR in humans to reduce the formation of antibodies to AAV capsids; and other products for the treatment of pompe disease, duchenne muscular dystrophy, and limb-girdle muscular dystrophy. In addition, it develops a product candidate to treat primary biliary cholangitis. The company has license and collaboration agreements with Swedish Orphan Biovitrum; Spark Therapeutics; Massachusetts Institute of Technology; Shenyang Sunshine Pharmaceutical Co., Ltd.; Asklepios BioPharmaceutical, Inc. Sarepta Therapeutics, Inc.; and IGAN Biosciences, Inc. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.